RECOMMENDATIONS FOR THE PERFORMANCE OF BACTERIAL MUTATION ASSAYS

被引:156
作者
GATEHOUSE, D
HAWORTH, S
CEBULA, T
GOCKE, E
KIER, L
MATSUSHIMA, T
MELCION, C
NOHMI, T
OHTA, T
VENITT, S
ZEIGER, E
机构
[1] BIOTRACE LABS, SALT LAKE CITY, UT 84119 USA
[2] US FDA, HFF 235, MOLEC BIOL BRANCH, WASHINGTON, DC 20204 USA
[3] F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND
[4] MONSANTO CO, ENVIRONM HLTH LAB, ST LOUIS, MO 63110 USA
[5] JAPAN BIOASSAY LAB, KANAGAWA 257, JAPAN
[6] RHONE POULENC RORER, F-92165 ANTONY, FRANCE
[7] NATL INST HYG SCI, TOKYO 158, JAPAN
[8] INST CANC RES, HADDOW LABS, SUTTON, SURREY, ENGLAND
[9] NIEHS, ENVIRONM TOXICOL PROGRAM, RES TRIANGLE PK, NC 27709 USA
来源
MUTATION RESEARCH | 1994年 / 312卷 / 03期
关键词
BACTERIAL MUTATION ASSAYS; RECOMMENDATIONS; STANDARDIZATION; GENOTOXICITY TEST PROCEDURES;
D O I
10.1016/0165-1161(94)90037-X
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
At the International Workshop on the Standardisation of Genotoxicity Test Procedures, in Melbourne (27-28 February 1993), the current international guidelines for the correct conduct of bacterial mutation assays were considered, and the major differences between them were examined. An attempt was made to construct a scientifically based, internationally harmonised protocol. The main points of agreement were as follows. The consensus opinion was that there are currently insufficient data to justify a preference for either the preincubation or plate-incorporation methodologies as the initial test. Whichever method is used there was consensus agreement that the bacterial test battery should consist of S. typhimurium TA1537, TA1535, TA98 and TA100. There was also consensus that the 3 strains TA97a, TA97 and TA1537 could be used interchangeably. Although it was not possible to achieve a consensus, the majority of the working group members agreed that strains for the detection of mutagens acting specifically on AT base pairs should be routinely included within the test battery. These strains may be S. typhimurium TA102 or E. coli WP2 strains (WP2 pKM101 and WP2 uvrA or WP2 uvrA pkM101). With regard to study design it was universally agreed that 5 doses of test compound should be used in each experiment, and a majority agreement was obtained for 3 plates per dose. The use of 2 plates per dose is acceptable ONLY if the experiment is repeated. It is recommended that the negative controls may consist of solvent control alone provided that historical data are available to demonstrate lack of effect of the solvent in question. Positive control compounds should be included in all experiments, although the nature of these control compounds need not be specified in the guidelines. There was consensus agreement that for non-toxic freely soluble test agents, an upper limit of 5 mg/plate should be tested (5 mu l per plate for liquids). For insoluble or toxic compounds, the recommendations were the same as those for other in vitro tests (see appropriate paper). A consensus agreement was reached on the need to carry out further tests if equivocal results are obtained in the initial test, although it was generally agreed that the design of the repeat study should be left flexible. As there are little or no data to support the use of an exact repeat assay, a majority of the group recommended that negative results in the first test should be further investigated by either conducting a modified repeat (e.g. S9 titration) or by conducting the alternative methodology. If a preincubation assay is carried out, an incubation time within the range 20-60 min is recommended, usually at a temperature of 37 degrees C. Lastly, a consensus agreement on the acceptable criteria for a positive or negative result could not be reached. There was majority agreement that a reproducible dose-response was necessary for a chemical to be classified as positive. A number of limitations of the proposed test methodology were recognised and included the adequate testing of specific chemical classes or groups, (i.e. ate-dyes and diazo compounds, gases, volatile chemicals and glycosides). Such 'special cases' should be evaluated using alternative published procedures.
引用
收藏
页码:217 / 233
页数:17
相关论文
共 43 条
[1]   PHENOBARBITAL - DOES THE POSITIVE RESULT IN TA1535 INDICATE GENOTOXIC PROPERTIES [J].
ALBERTINI, S ;
GOCKE, E .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1992, 19 (02) :161-166
[2]   PLASMID COPY NUMBER AND MUTANT FREQUENCIES IN S-TYPHIMURIUM TA102 [J].
ALBERTINI, S ;
GOCKE, E .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1988, 12 (04) :353-363
[3]  
ARAKI A, 1984, GANN, V15, P8
[4]  
ARAKI A, 1988, TOXICOLOGY FORUM, V11, P184
[5]   WEAK MUTAGENICITY TO SALMONELLA OF THE FORMALDEHYDE-RELEASING ANTI-TUMOR AGENT HEXAMETHYLMELAMINE [J].
ASHBY, J ;
CALLANDER, RD ;
ROSE, FL .
MUTATION RESEARCH, 1985, 142 (03) :121-125
[6]   CYTOSOLIC ACTIVATION OF 2-AMINOANTHRACENE - IMPLICATIONS IN ITS USE AS DIAGNOSTIC MUTAGEN IN THE AMES TEST [J].
AYRTON, AD ;
NEVILLE, S ;
IOANNIDES, C .
MUTATION RESEARCH, 1992, 265 (01) :1-8
[7]   THE RELATIONSHIP BETWEEN GROWTH AND REVERSION IN THE AMES SALMONELLA PLATE INCORPORATION ASSAY [J].
BARBER, ED ;
DONISH, WH ;
MUELLER, KR .
MUTATION RESEARCH, 1983, 113 (02) :89-101
[8]   COMPARATIVE MUTAGENICITY OF N-NITROSAMINES IN A SEMISOLID AND IN A LIQUID INCUBATION SYSTEM IN PRESENCE OF RAT OR HUMAN TISSUE FRACTIONS [J].
BARTSCH, H ;
CAMUS, A ;
MALAVEILLE, C .
MUTATION RESEARCH, 1976, 37 (2-3) :149-162
[9]  
BONNEAU D, 1991, MUTAT RES, V252, P269, DOI 10.1016/0165-1161(91)90006-T
[10]  
de Serres F. J., 1981, PROGR MUTATION RES, V1